TGF-β Family Signaling in Development and Disease
About This Grant
Abstract The FASEB SRC TGF-β family in Development and Disease in 2026 (hereafter "TGF-β 2026") will convene investigators who are advancing TGF-β research, from fundamental discovery through clinical application. This gathering unites researchers across the full spectrum of the TGF-β family, which encompasses over 30 ligands including TGF-βs, BMPs, GDFs, activins, and inhibins, who are driving innovations in cancer immunotherapy, regenerative medicine, vascular therapeutics, and age-related interventions. The conference program emphasizes mechanistic insights that inform therapeutic development, featuring sessions on cancer signaling mechanisms, development-disease intersections, vascular physiology and angiogenesis, tissue homeostasis, stem cell biology and regeneration, structure-function, and strategic therapeutic avenues. These presentations will showcase how advances in understanding TGF-β pathway regulation are being translated into clinical solutions for cancer, cardiovascular disease, immune disorders, musculoskeletal conditions, and aging-related pathologies. TGF-β 2026 represents the 14th iteration of this premier conference series, now spanning nearly 25 years of scientific evolution that has paralleled the field's maturation from basic signaling studies to therapeutic targeting. The sustained research momentum, with continued high publication and funding rates across TGF-β research domains, reflects the field's transition toward clinical impact and commercial development. This conference also bridges academic discovery with industry innovation, featuring speakers from leading pharmaceutical companies alongside academic researchers, creating opportunities for translational partnerships and therapeutic advancement discussions. The 2026 meeting will also foster cross- continental partnerships that have become essential for modern therapeutic development. Drawing from 13 previous conferences, TGF-β 2026 provides an intensive forum for sharing evaluating therapeutic targets, discussing regulatory pathways in model systems, and addressing translational challenges. The conference particularly emphasizes developing the next generation of TGF-β researchers equipped for the increasingly interdisciplinary and translational nature of the field, ensuring continued progress toward therapeutic breakthroughs that benefit human health.
Grant Summary
TGF-β Family Signaling in Development and Disease is a NCI - National Cancer Institute grant providing up to $20K for university, nonprofit, healthcare org. Applications are due 2027-06-30 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $20K
2027-06-30
- 1Confirm your organization is eligible for TGF-β Family Signaling in Development and Disease from NCI - National Cancer Institute, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NCI - National Cancer Institute before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NCI - National Cancer Institute's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
TGF-β Family Signaling in Development and Disease: Frequently Asked Questions
Who is eligible for the TGF-β Family Signaling in Development and Disease?
TGF-β Family Signaling in Development and Disease is offered by NCI - National Cancer Institute and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the TGF-β Family Signaling in Development and Disease provide?
TGF-β Family Signaling in Development and Disease provides up to $20K per award from NCI - National Cancer Institute. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the TGF-β Family Signaling in Development and Disease deadline?
Applications for TGF-β Family Signaling in Development and Disease are due 2027-06-30 (open). Because deadlines can change, verify the date with the funder, NCI - National Cancer Institute, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the TGF-β Family Signaling in Development and Disease?
To apply for TGF-β Family Signaling in Development and Disease, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NCI - National Cancer Institute.